Toxicities of systemic cancer therapies are often less frequently observed in clinical trials than in clinical practice, due to the careful selection of patients with fewer comorbidities. Although guidelines exist for the estimation of chemotherapy dose, clinical factors like age, comorbid illness and extremes of body habitus are not considered in the method of dose calculation, which can result in significant toxicity. We reviewed the referenced clinical trials from which the evidencebased curative-intent cancer treatment protocols were developed for EVIQ, which is an Australian government, online resource. This review shows that a significant proportion of patients in curative-intent clinical trials experience toxicities that result in dose modifications-dose reduction, dose delays or missed doses-despite strict selection criteria and intense monitoring. 
INTRODUCTION
The optimal dose of chemotherapeutic agents used in the management of malignancy remains a subject of debate. It is well established that adequacy of dosing is critical for lethal, yet potentially curable cancers such as diffuse large B-cell lymphoma or metastatic testicular germ cell tumors. 1, 2 However, in the context of adjuvant, risk-reducing therapies such as those used in early breast, colorectal (CRC), non-small cell lung (NSCLC) and pancreatic cancers, decisions relating to cytotoxic treatment are complicated by the knowledge that for many patients, toxic therapy may be unnecessary, whereas in others it is futile, especially in cancers with relatively favourable natural history, like breast and colorectal cancer. Discussions with patients are often complex undertakings weighing up the likely benefit in risk-reduction versus the risk of significant if not potentially fatal adverse events.
Calculation of drug dosing is initially undertaken with preclinical testing, followed by phase I/II trials. Phase I trials are aimed at finding the recommended phase II dose, which is then used in the subsequent phases. Further dose escalation is extremely rare in phase II/III trials irrespective of the clinical efficacy, and in fact dose reduction may be required as new toxicities become apparent.
Despite the use of the recommended doses from clinical trials, in real-world practice the proportion of patients that experience serious toxicities may be higher than that observed in clinical trials. This is likely due to the careful selection of patients in clinical trials who have a good performance status, and the frequent utilization of other supportive therapies such as granulocyte-colony stimulating factor (G-CSF). 3, 4 For example, a retrospective analysis by Lakhanpal et al. found the incidence of febrile neutropenia with adjuvant docetaxel/cyclophosphamide (TC) chemotherapy used for breast cancer in Australian community practice was 25%. 3 In comparison, in the definitive trial by Jones et al. 5 comparing adjuvant TC to doxorubicin/cyclophosphamide (AC) the incidence was only 2.4% with TC. In a review, Weycker et al. 6 reported rates of febrile neutropenia between 8.8% and 10.6%, albeit in settings where more than 50% of patients received G-CSF as primary prophylaxis. Many other series 7, 8 Febrile neutropenia rates were higher (11.5%) than what was seen in TROPIC trial (8%) despite use of G-CSF as primary prophylaxis in 47% of patients. 10 However, a subsequent trial comparing 20 with 25 mg/m 2 showed non-inferiority with less toxicity. 11 In 2016, the NSW Department of Health recommended that chemotherapy protocols should adhere to those published on the EVIQ website. 12 EVIQ is an Australian government, online resource of evidence-based cancer treatment protocols developed by multidisciplinary teams of cancer specialists with a goal to improve patient outcomes and reduce treatment variation. In the adjuvant setting higher dose intensity is associated with better overall survival (OS) and disease-free survival (DFS) in breast cancer. 13, 14 However, although treatment-related mortality is low in the adjuvant setting, 15,16 many oncologists will have seen their patients endure significant and occasionally life-threatening toxicity. Therefore, the recommendations of the NSW Department of Health acknowledged that medical oncologists may modify these treatment protocols where clinically appropriate. Nevertheless, recent media discussion surrounding chemotherapy dosing has almost invariably failed to discuss the nuances of chemotherapy dose calculation, nor the particular aspects of individual benefit versus risk in the adjuvant setting. Anecdotally, many oncologists now face resistance from patients to recommended chemotherapy dose modifications despite significant toxicity. Herein we review the chemotherapy trials upon which the EVIQ chemotherapy protocols for curative-intent treatment of common solid organ malignancies and analyse the actual dosing in the trials and reported dose modifications in these trials.
METHODS
We selected commonly used curative-intent (adjuvant/neoadjuvant/ radiosensitizing) chemotherapy protocols for breast, lung, colorectal, head and neck, bladder, gastro-oesophageal and pancreatic cancers.
Clinical trial data, from which the protocols were developed for EVIQ were collected from the publications referenced on the EVIQ site. Recommended doses from each protocol, the proportion of patients who completed the planned treatment (completion rate), dose modifications, grade 3-4 toxicities and death rates were collected.
RESULTS
Twenty-eight curative-intent trials were identified from the EVIQ website ( Table 1 ). The reporting pattern of dose modification, rate of completion of planned chemotherapy and toxicity of treatment varied between trials. The median age across all reviewed trials ranged from 49 to 63 years.
Head and neck cancer
The head and neck cancer trials with concurrent chemoradiation included cisplatin, carboplatin or cetuximab either three weekly or weekly. Toxicity was higher with three weekly cisplatin with only 73% completing all planned cycles. Protocol completion rate was high with weekly regimens ranging from 80% to 92%. However, only 73% completed the planned cycles of weekly carboplatin in the trial by Chitapanarux et al. 17 Most of the trials were designed to allow dose modifications and interruptions, and varying rates of dose modifications were seen across the trials, Sharma et al. 18 reporting 29% interruption with chemotherapy. Two trials reported 3-4% unacceptable protocol dose deviations, and 43% acceptable dose deviations. 19, 20 The major chemotherapy-related toxicity was neutropenia (10-30%).
Colorectal cancer
In colorectal/anal cancer studies, the protocol completion rate was 69% and 75% for oxaliplatin in the XELOXA 21 and MOSAIC 22 trials respectively whereas it was higher in the X-ACT 23 trial with capecitabine at 83%. A total of 20% and 62% of patients required dose modification of oxaliplatin in the MOSAIC and XELOXA studies with whereas 57% needed dose modification of capecitabine in the X-ACT trial. In the latter study, dose reduction did not have any impact on the survival. 23 In the trial by James et al. for anal cancer, 91% completed concurrent chemoradiotherapy, whereas only 41% completed the maintenance chemotherapy. 24 
Lung cancer
Chemotherapy completion occurred in up to 50%, and there were significant dose reductions in 77-81% of patients. In the ANITA trial, only 38% of patients managed to receive more than two-thirds of the dose of vinorelbine whereas only 63% received more than two-thirds of the recommended cisplatin dose. 25 Eighty-one percent completed maintenance docetaxel in the trial by Hanna et al., with 11% rates of febrile neutropenia. 26 
Bladder, gastro-oesophageal and pancreatic cancer
The protocol completion rate was 87-96% in bladder cancer trials with 7% dose reductions reported in the trial of accelerated methotrexate, vinblastine, doxorubicin, cisplatin (MVAC). 27 The rate of febrile neutropenia was 2-18%. 28, 29 Preoperative chemotherapy was delivered in 91% and 95% of patients in the CROSS 30 33 In pancreatic cancer, adjuvant trials 60-62% required dose modifications. 34, 35 TA B L E 1 Dose modification, completion rate and significant side effects of adjuvant chemotherapy trials 
Breast cancer
Seven adjuvant breast cancer were included in this review. The rate of protocol completion of the planned chemotherapy was high in these trials, ranging from 91% to 97%. In the NSABP B28 trial, 36 only 75% of patients received all planned cycles of paclitaxel, whereas dose modification was required with weekly paclitaxel in 29% of patients in the trial by Sparano et al. 37 The rate of grade 3/4 neutropenia was 25-65% in most of the breast cancer trials with 1-28% febrile neutropenia. The highest rate of febrile neutropenia was with the docetaxel/doxorubicin/cyclophosphamide (TAC) regimen at 28% despite the use of prophylactic antibiotics, 38 
Deaths
Across all curative-intent clinical trials, the treatment-related deaths were infrequent. In the head and neck cancer study reported by Newlin et al. and in the MOSAIC colorectal cancer trial there were 3 (2%) and 6 (0.5%) treatment-related deaths respectively. 22, 42 In NSCLC, the 
DISCUSSION
The protocol completion rates and dose modifications in curativeintent chemotherapy trials are variable. Protocol completion rate was less than 90% in many of the non-breast cancer trials and dose modifications were required in 3-40%, mostly due to hematological toxicity. The protocol completion rate was higher in breast cancer trials, with more than 90% of patients able to complete their planned doses of chemotherapy. This is likely due to differences in the study populations compared to non-breast cancer adjuvant chemotherapy trials. Breast cancer trial populations were younger than other groups and likely to have less comorbidities with good performance status, although the performance status was not well reported. Nevertheless, even in this highly selected population there were noticeable rates of treatment toxicity and dose modification was required in many of the breast cancer studies (Table 1) . None of the clinical trials reported a separate analysis and outcome of those patients who required dose modification except the XELOXA trial, in which there was no impact of dose modification on DFS. 21 In clinical practice, higher rates of dose modification are reported due to factors which may influence concern around drug handling such as abnormal hepatic function, renal function and serum albumin, and in those with poor performance status, extremes of age and coexisting medical conditions. Shayne et al. looked at the dose delays and dose reductions of breast cancer adjuvant chemotherapy in 190 community-based oncology practices and found 20% of patients had a dose reduction of 15% or more and 31% had a delay in chemotherapy dosing. Thirty percent of patients received less than 85% of their planned dose, 17% of which were planned and 13% of which were unplanned. Predictive factors for dose reduction were age >65 years, body surface area (BSA) >2 m 2 , comorbidities and negative lymph nodes. Most dose reductions were due to hematological toxicities.
Although the treatment-related deaths were infrequent, there were 0.16% deaths reported out of 16 696 patients (0.07% in breast cancer and 0.3% in non-breast cancer trials) in the investigational arm of the trials included in this review. It is possible that treatment-related deaths are likely to be higher in the community-based oncology practice. Patients on clinical trials are a highly selected population without many of these confounding factors. Hence, the disparity in the rates of toxicity and extent of dose modification in clinical trials and in the community is understandable. 3 Further, these inherent differences are reflected in the superior outcomes of patients on clinical trials compared to those treated in real-world settings. 44 Some of the common factors implicated in chemotherapy dosing in clinical practice are discussed here.
The issue of BSA and body weight
BSA is the most-commonly used method used to calculate chemotherapy dose for individual patients. Methods such as that developed by Dubois and Dubois are reasonably accurate in estimating the BSA itself. 45 However, the use of the BSA for the calculation of chemotherapy dosing is controversial as it does not account for other factors that may influence drug handling such as extremes of age, extremes of weight and pharmacogenomic variability.
Many oncologists practice capping the BSA at 2 m 2 or using ideal body weight for dose calculation in the belief that higher doses in such patients may lead to excessive toxicity. 46 However, many studies have reported that dose reduction in obese patients may result in inferior outcome, [47] [48] [49] although high-toxicity rates has been reported in patients with a BSA of more than 2 m 2 . 50 Current ASCO guidelines recommend using actual body weight for obese patients. 51 Data are scarce regarding dosing in underweight patients. Sarcopenia, which is common among advanced cancer patients, although under reported, may be associated with poor outcome and increased toxicity. 52, 53 In the absence of an alternative method of dosing, a cautious approach is needed when using full body weight based calculation and other factors like performance status, organ function should be taken into consideration for all patients.
Age
Older patients are often underrepresented in clinical trials. This age group does not always receive standard therapies due to their comorbidities and justifiable fear of toxicity. 54 There are varying physiological changes that occur in the elderly, including changes in organ function and volume of distribution which may affect drug handling and could result in excessive toxicity compared to younger population. 55 Muss et al. reported a higher incidence of treatment-related deaths in older women in a pooled analysis of three breast cancer clinical trials. 56 There are also reports suggesting an increased incidence of congestive cardiac failure and acute myeloid leukaemia in older patients treated with anthracycline-based chemotherapy. 57, 58 Elderly patients have higher odds of dying from competing causes other than cancer, 59 yet 40% of women die of breast cancer when the initial diagnosis is at more than 80 years of age. 60 In this setting, there should be a thorough discussion with the patient about the extent of benefit and degree of risk associated with cytotoxic chemotherapy. Both patient and oncologist should understand the physiological changes and potential toxicities before agreeing upon an appropriate regimen and dosing in this high-risk population.
Ethnicity
Pharmacokinetics and pharmacogenomics in individuals within the same community and between different communities may vary, resulting in differing efficacy and toxicity despite identical dose calculations based on BSA. Many studies have found differential toxicities in African
Americans compared to Caucasians. [61] [62] [63] There are only a few studies examining the differences between Asians and other populations. 64, 65 One study of 34 Japanese patients in a U.S.-based head and neck cancer trial of docetaxel, 5-fluorouracil and cisplatin found that the Japanese cohort of patients managed to receive only 80% of the total dose given to the U.S. cohort with a higher rate of grade 3-4 neutropenia. 65 Another Australian study further reinforces the ethnic differences in cancer therapeutics. 66 In this study, carboplatin and paclitaxel for advanced NSCLC resulted in an almost 50% incidence of febrile neutropenia in the early cohorts of Asian patients, and necessitated dose reductions for subsequent cohorts.
Despite dose modifications, febrile neutropenia rates were as high as 40% in Asian patients. It is also noteworthy that this study included patients from both Asia and Australia and that the tumour response rate was doubled in Asians compared to the predominantly Caucasian
Australian cohort.
The current method of dose calculation is based on trials enrolling predominantly Caucasian populations. Nonetheless no other reliable, cost effective method of dose calculation has yet been implemented.
Importantly, the Australian community is ethnically diverse, leading to some concern as to the general applicability of strict protocol-based dosing in current community practice. 
